These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Drivers of Hsp104 potentiation revealed by scanning mutagenesis of the middle domain. Ryan JJ; Bao A; Bell B; Ling C; Jackrel ME Protein Sci; 2021 Aug; 30(8):1667-1685. PubMed ID: 34010483 [TBL] [Abstract][Full Text] [Related]
12. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. Tariq A; Lin J; Noll MM; Torrente MP; Mack KL; Murillo OH; Jackrel ME; Shorter J FEMS Yeast Res; 2018 Aug; 18(5):. PubMed ID: 29788207 [TBL] [Abstract][Full Text] [Related]
17. Purification of hsp104, a protein disaggregase. Sweeny EA; DeSantis ME; Shorter J J Vis Exp; 2011 Sep; (55):. PubMed ID: 21989490 [TBL] [Abstract][Full Text] [Related]
18. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. Lo Bianco C; Shorter J; Régulier E; Lashuel H; Iwatsubo T; Lindquist S; Aebischer P J Clin Invest; 2008 Sep; 118(9):3087-97. PubMed ID: 18704197 [TBL] [Abstract][Full Text] [Related]
19. Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson's disease. Gade VR; Kardani J; Roy I Int J Biochem Cell Biol; 2014 Oct; 55():87-92. PubMed ID: 25161148 [TBL] [Abstract][Full Text] [Related]
20. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. Shorter J PLoS One; 2011; 6(10):e26319. PubMed ID: 22022600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]